Synthekine Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
70
- Latest Deal Type
-
Series D
- Investors
-
13
Synthekine General Information
Description
Developer of engineered cytokine therapeutics designed to facilitate disease-optimized treatments. The company leverages immunological insights to guide targeted protein engineering and generate transformative medicines, enabling the medical community to optimize the treatment of cancer and autoimmune disorders.
Contact Information
Website
www.synthekine.comCorporate Office
- 1505 O'Brien Drive
- Menlo Park, CA 94025
- United States
Corporate Office
- 1505 O'Brien Drive
- Menlo Park, CA 94025
- United States
Synthekine Timeline
Synthekine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series D) | 21-Oct-2025 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 06-Dec-2022 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series B) | 10-Jun-2021 | $108M | $189M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 17-Sep-2020 | $81.1M | $81.1M | Completed | Pre-Clinical Trials |
Synthekine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A-1 | 31,999,998 | $0.000010 | 8% | $1.25 | $1.25 | 1x | $1.25 | 16.52% |
| Series A | 41,111,110 | $0.000010 | 8% | $1 | $1 | 1x | $1 | 21.23% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Synthekine Comparisons
Industry
Financing
Details
Synthekine Competitors (1)
One of Synthekine’s competitors is CytoAgents, a Venture Capital-Backed company based in Pittsburgh, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytoAgents | Venture Capital-Backed | Pittsburgh, PA |
Synthekine Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Synthekine Patents
Synthekine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026107319-A2 | Car-t cell therapy of autoimmune disease-associated joint inflammation | Pending | 15-Nov-2024 | ||
| WO-2026107319-A3 | Car-t cell therapy of autoimmune disease-associated joint inflammation | Pending | 15-Nov-2024 | ||
| WO-2025207624-A1 | Compositions and methods useful in the treatment of autoimmune disease | Pending | 25-Mar-2024 | ||
| AU-2024286534-A1 | Humanized il-10 receptor binding molecules and methods of use | Pending | 07-Jun-2023 | ||
| EP-4724483-A2 | Humanized il-10 receptor binding molecules and methods of use | Pending | 07-Jun-2023 | C07K16/244 |
Synthekine Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Synthekine Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Revelation Partners | Venture Capital | Minority | ||
| Bain Capital Life Sciences | Corporate Venture Capital | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| Janus Henderson Investors | Asset Manager | Minority | ||
| LAV (Lilly Asia Fund) | Corporate Venture Capital | Minority |
Synthekine FAQs
-
When was Synthekine founded?
Synthekine was founded in 2018.
-
Where is Synthekine headquartered?
Synthekine is headquartered in Menlo Park, CA.
-
What is the size of Synthekine?
Synthekine has 70 total employees.
-
What industry is Synthekine in?
Synthekine’s primary industry is Drug Discovery.
-
Is Synthekine a private or public company?
Synthekine is a Private company.
-
What is Synthekine’s current revenue?
The current revenue for Synthekine is .
-
How much funding has Synthekine raised over time?
Synthekine has raised $289M.
-
Who are Synthekine’s investors?
Revelation Partners, Bain Capital Life Sciences, Deerfield Management, Janus Henderson Investors, and LAV (Lilly Asia Fund) are 5 of 13 investors who have invested in Synthekine.
-
Who are Synthekine’s competitors?
CytoAgents is a competitor of Synthekine.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
